- Inuvo (INUV +2.7%) announced preliminary revenues of ~$19M (+4% Y/Y) for Q2 and $39.5M (+11% Y/Y) for 1H.
- “First half revenue growth of 11% is aligned with our expectations and guidance. We typically have a weak month during the first half of the year, which fell in April this year. Historically, this has defined the relative growth rates year over year between first quarter and the second quarter and explains why the first half growth rate is a good indicator for the overall year. We grow more excited every day about the potential for and the differentiation of, our IntentKeyTM technology. We reiterate guidance for the current year, expecting double digit revenue growth over 2017 with higher adjusted EBITDA,” stated Rich Howe, Executive Chairman of Inuvo.
- The Company expects to announce Q2 results on August 8.
- Now read: BELLUS Health launches early-stage of lead drug BLU-5937 for chronic cough; shares up 4%
Original article